All In Biotech

Drug Trial Radar · NCT06943404

BXCL501 After Stress to Increase Recovery Success

Prevention/Reduction of ASRs and PTSD to Sustain Civilian Performance With a Sublingual Formulation of Dexmedetomidine (BXCL501)

Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 100 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

Feb 23, 2026

Primary completion

Sep 29, 2027

Study completion Sep 29, 2027

Sponsor

Lead sponsor
University of North Carolina, Chapel HillAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
United States Department of Defense; Mclean Hospital; Washington University School of Medicine; University of Florida; Rhode Island Hospital; Vanderbilt University School of Medicine; Walter Reed Army Institute of Research (WRAIR); Lakeland Regional Health Systems, Inc.
First posted
Apr 24, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will examine the safety and efficacy of BXCL501 to reduce ASR symptoms and behavioral changes among patients presenting to the Emergency Department (ED) after Motor Vehicle Collision (MVC). Specifically, the investigators will perform the BXCL501 (BASIS) Trial, a double-blind placebo-controlled Randomized Controlled Trial (RCT) to determine if BXCL501 (dexmedetomidine hydrochloride sublingual film) initiated in the ED in the hours after MVC to high risk individuals, treats/reduces ASR/ASD symptoms (primary outcome), improves neurocognitive function, and prevents/reduces posttraumatic stress (PTS) symptoms (secondary outcomes) long term. 100 participants will be randomized, receive study drug in ED and be discharged with a 2-week drug supply. Prior to initial dose of study drug administration, and during the hours, days, and weeks after participants will receive serial longitudinal assessments of psychological and somatic symptoms, neurocognitive function, and adverse events.

Conditions

  • Acute Stress Reaction
  • Acute Stress Disorder
  • Post-traumatic Stress Disorder

Interventions

  • BXCL501 (dexmedetomidine HCl)Drug

    BXCL501 (dexmedetomidine HCl) taken sublingually (under the tongue) in the ED and at bedtime over 2 weeks.

  • PlaceboDrug

    Placebo taken sublingually (under the tongue) in the ED and at bedtime over 2 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in ASD ScoreTime frame: Week 1, 3 after MVC

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • University of Florida College of Medicine - Jacksonville

    Jacksonville, Florida · Recruiting

  • Lakeland Regional Health

    Lakeland, Florida · Recruiting

  • Washington University in St. Louis

    St Louis, Missouri · Not yet recruiting

  • UVA University Hospital

    Charlottesville, Virginia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.